Add to watchlist
$406.14
Last updated:06/14/2021
BIIB: NASDAQ
Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADE… Show more

P/E ratio
21.05x
vs. 21.55x forward

Price is 21.05x times more than EPS $19.29 which eaquals $406.14

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
2.5391B
4.4307B
+74.50%
5.8885B
+32.90%
4.0006B
-32.06%
Cashflow
Sum up money going in and out company
4.551B
6.1877B
+35.96%
7.0786B
+14.40%
4.2298B
-40.25%
Total liabilities
All combined debts and obligations
11.0545B
12.2573B
+10.88%
13.8952B
+13.36%
13.9328B
+0.27%
Stock exposure in ETFs
ETF
Percentage of ETF
Become a premium member and see all 57 ETFs that include this stock
Company profile
CEO
Mr. Michel Vounatsos
Market capitalization
Mega (61.27B)
BIIB price history
Loading price stock history...